We are building a biosimilar portfolio across multiple disease areas, including autoimmune diseases, cancer, hematology, osteoporosis and other areas of high healthcare need. Our goal is to help expand access to high-quality biologic medicines while supporting more sustainable healthcare systems.
Our Biopharma portfolio
Biopharma approved products
Product | Molecule / active substance | Class / target |
| IDACIO® | adalimumab | TNFα monoclonal antibody |
| BOMYNTRA® | denosumab | RANKL monoclonal antibody |
| CONEXXENCE® | denosumab | RANKL monoclonal antibody |
| STIMUFEND® | pegfilgrastim | G-CSF analogue |
| TYENNE® | tocilizumab | IL-6 receptor monoclonal antibody |
| OTULFI® | ustekinumab | IL-12 / IL-23 monoclonal antibody |
Biopharma pipeline
Our pipeline includes more than 15 biosimilar assets in development across major therapeutic areas.
Therapeutic area | Example focus |
| Autoimmune diseases | Immunology, inflammatory and gastroenterology conditions |
| Bone health | Osteoporosis and related conditions |
| Endocrinology | Chronic metabolic conditions |
| Hematology | Blood disorders |
| Oncology | Cancer and supportive care |
| Ophthalmology | Retinal diseases |
| Respiratory diseases | Severe inflammatory respiratory conditions |
Important information about prescription medicines
We cannot provide detailed information about our prescription medicines on this global website, in compliance with applicable regulations.
Our medicines are approved in individual countries for specific uses, and the information we provide for patients is governed by local regulations. In some cases, healthcare professionals and patients can visit local Fresenius Kabi websites to find out more about our medicines. Please note that in some countries we are not allowed to provide detailed, or sometimes any information on prescription medicines. Please seek information from reliable local sources and always ask a healthcare professional for advice about medicines.
Reporting side effects
The safety of patients is very important to us. If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.
By reporting side effects, you can help provide more information on the safety of medicines. You can report a possible side effect to Fresenius Kabi using the Report side effect link below.